Evogene (EVGN) Stock Price, News & Analysis

Company Overview

Evogene Ltd. is a biotechnology company that develops computational biology technologies to discover and develop products based on microbes, small molecules and genetic traits. Its proprietary computational platforms are designed to analyze biological data and identify candidates with potential applications in agriculture, human health and industrial biotechnology.

The company has historically pursued these opportunities through subsidiaries and partnerships. Its activities have included the development of biological crop-protection and crop-enhancement products, microbiome-based therapies and solutions, and cannabis-related medical technologies. Evogene’s agricultural activities have included microbial products intended to improve crop performance and protect plants, while its health-related programs have focused on identifying therapeutic candidates and microbiome-based treatments.

Evogene was founded in Israel in 1999 and is headquartered in Rehovot, Israel. Ofer Haviv, a co-founder of the company, has served as its president and chief executive officer. The company serves global agricultural, pharmaceutical and biotechnology markets through research, development, licensing and collaboration arrangements.

Key Stats

• Today's Range: $0.35 to $0.45
• 50-Day Range: $0.42 to $0.70
• 52-Week Range: $0.35 to $1.50
• Volume: 170,771 shs
• Average Volume: 834,810 shs
• Market Capitalization: $3.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Evogene Stock Analysis - MarketRank™

Evogene scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Evogene has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Evogene has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evogene is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evogene is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evogene has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.70% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently increased by 7.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evogene does not currently pay a dividend.

Dividend Growth

Evogene does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Evogene has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Evogene this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $294,400.00 in company stock, which represents 8.8866% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Evogene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $294,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of Evogene is held by insiders.

Percentage Held by Institutions

10.40% of the stock of Evogene is held by institutions.

Company Calendar

• Last Earnings: 5/16/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EVGN
• CIK: 1574565
• Web: www.evogene.com
• Phone: (728) 931-1900
• Fax: 972-8946-6724
• Employees: 52
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.48 million
• Net Margins: -694.18%
• Pretax Margin: -1,230.53%
• Return on Equity: -156.53%
• Return on Assets: -86.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.57
• Quick Ratio: 3.54

Sales & Book Value

• Annual Sales: $1.66 million
• Price / Sales: 2.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 8,718,000
• Free Float: 8,073,000
• Market Cap: $3.31 million
• Optionable: No Data
• Beta: 1.41